To improve or induce responses to anti–PD-1/anti–PD-L1 treatment in a checkpoint-unresponsive cancer, a therapy that promotes both T-cell infiltration into tumors and immunogenicity of the tumor itself is desirable. This evidence concerns the gene PDCD1 and cancer.